ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

20 фев 2024 10:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

06 фев 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

29 янв 2024 07:24:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

22 янв 2024 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

21 дек 2023 00:30:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

04 дек 2023 16:35:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

04 дек 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

27 ноя 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

16 ноя 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

08 ноя 2023 07:25:00 Источник Nasdaq GlobeNewswire

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

30 окт 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

31 авг 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

23 авг 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

22 авг 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

15 авг 2023 07:25:00 Источник Nasdaq GlobeNewswire

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

31 июл 2023 07:52:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

26 июл 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

21 июн 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

30 май 2023 07:25:00 Источник Nasdaq GlobeNewswire

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

19 май 2023 07:25:00 Источник Nasdaq GlobeNewswire